Pictet Asset Management
BCRX icon

Pictet Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Pictet Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12M Buy
1,249,771
+778,198
+165% +$7.04M 0.01% 648
2026
Q1 		$4.46M Sell
471,573
-268,937
-36% -$2.09M ﹤0.01% 796
2025
Q4 		$5.71M Sell
740,510
-455,809
-38% -$3.3M 0.01% 781
2025
Q3 		$9.03M Buy
1,196,319
+227,278
+23% +$1.89M 0.01% 692
2025
Q2 		$9.06M Buy
969,041
+356,717
+58% +$3.32M 0.01% 670
2025
Q1 		$4.8M Buy
612,324
+585,882
+2,216% +$4.73M 0.01% 807
2024
Q4 		$199K Buy
26,442
+6,840
+35% +$51.9K ﹤0.01% 1859
2024
Q3 		$149K Hold
19,602
– – ﹤0.01% 1894
2024
Q2 		$121K Hold
19,602
– – ﹤0.01% 1862
2024
Q1 		$99.6K Hold
19,602
– – ﹤0.01% 1882
2023
Q4 		$117K Sell
19,602
-4,172,698
-100% -$24.2M ﹤0.01% 1855
2023
Q3 		$29.7M Buy
+4,192,300
New +$30.1M 0.04% 368

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Pictet Asset Management's BCRX Position: Q2 2026 in Review

Pictet Asset Management increased its BioCryst Pharmaceuticals (BCRX) stake by 165% in Q2 2026, buying an estimated $7.04M and bringing the position to 1,249,771 shares worth $12M. The position accounts for 0.01% of the portfolio, ranked #648.

Pictet Asset Management first reported a position in BCRX in Q3 2023 and has held it in 12 quarters since. The position peaked at $29.7M in Q3 2023. 319 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Pictet Asset Management held 1,249,771 shares of BioCryst Pharmaceuticals worth $12M as of Q2 2026.
  • Pictet Asset Management bought 778,198 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $7.04M.
  • BioCryst Pharmaceuticals made up 0.01% of Pictet Asset Management's portfolio in Q2 2026, its #648 holding.
  • Pictet Asset Management first reported a position in BioCryst Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • Pictet Asset Management's BioCryst Pharmaceuticals position peaked at $29.7M in Q3 2023.
  • 319 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.